Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Regad T, Targeting RTK. Signaling pathways in cancer. Cancers. 2015;7(3):1758–84.
2. Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105.
3. Syrigos KN, Saif MW, Karapanagiotou EM, et al. The need for third-line treatment in non-small cell lung cancer: an overview of new options. Anticancer Res. 2011;31(2):649–59.
4. Chia Tai Tianqing Pharmaceutical. Anlotinib hydrochloride capsules. 2018.
https://www.cttq.com
Accessed 29 May 2018.
5. Advenchen Laboratories. 2018.
http://advenchen.com
. Accessed 30 May 2018.
Cited by
175 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献